While several companies have started down the path of inhibiting the destructive effects of Th17 cells in rheumatoid arthritis and multiple sclerosis, Numab AG expects its bispecific antibodies will provide a greater therapeutic effect by eliminating Th17 and delta gamma T cells.

Published studies have shown T helper type 17 (Th17) and delta gamma T cells are responsible for producing inflammatory cytokines that trigger a variety of autoimmune diseases, such as interleukin-17 (IL-17), IL-21, IL-22 and granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2).